研究表明纤维蛋白原水平与乳腺癌患者的预后之间存在关联。然而，纤维蛋白原水平特别容易受到月经周期波动的影响。本研究探讨了绝经后乳腺癌女性术前血浆纤维蛋白原水平与术后预后之间的关系。对 855 名绝经后乳腺癌患者进行了为期 10 年的监测。使用 Cox 比例风险回归模型进行单变量和多变量分析，以确定具有重大预后价值的因素。中位随访时间为 77 个月（51-105 个月），最长为 142 个月。在随访期间，记录了 65 人死亡 (7.6%)。多变量Cox回归结果显示，术前血浆纤维蛋白原水平（风险比[HR]=1.615，95%置信区间[CI]：1.233-2.115）和年龄（HR=1.626，95%CI：1.250-2.116）是独立危险因素绝经后乳腺癌患者术后 10 年总生存率较高，而内分泌治疗（HR=0.414，95%CI：0.202-0.846）是一个独立的保护因素。多变量 Cox 回归结果还显示，术前血浆纤维蛋白原水平是 10 年无病生存率（HR = 1.398，95% CI：1.137-1.719）和 10 年无远处转移生存率（HR = 1.436， 95%CI：1.153-1.787)。治疗前血浆纤维蛋白原水平升高与手术治疗后绝经后乳腺癌患者的长期预后较差相关。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Studies have indicated an association between fibrinogen levels and the prognosis of breast cancer patients. However, fibrinogen levels are notably susceptible to fluctuations due to the menstrual cycle. This study explored the relationship between preoperative plasma fibrinogen levels and the prognosis of postmenopausal breast cancer women after surgery.855 patients with postmenopausal breast cancer were monitored for 10 years. Cox proportional hazards regression models were used to perform univariate and multivariate analyses to identify factors that are of substantial prognostic value.The median follow-up was 77 months (51-105 months), and the maximum 142 months. Over the follow-up period, 65 deaths (7.6 %) were recorded. Multivariate Cox regression results show that preoperative plasma fibrinogen level (hazard ratio [HR] =1.615, 95 % confidence interval [CI]: 1.233-2.115) and age (HR = 1.626, 95%CI: 1.250-2.116) were independent risk factors for 10-year overall survival after surgery in postmenopausal breast cancer patients, while endocrine therapy (HR = 0.414, 95%CI: 0.202-0.846) was an independent protective factor. Multivariate Cox regression results also show preoperative plasma fibrinogen level was an independent risk factor for 10-year disease-free survival (HR = 1.398, 95 % CI: 1.137-1.719) and 10-year distant metastasis-free survival (HR = 1.436, 95%CI: 1.153-1.787).Elevated pretreatment plasma fibrinogen levels are associated with a poorer long-term prognosis in postmenopausal breast cancer patients following surgical treatment.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.